These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16766651)

  • 1. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.
    Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA
    Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA.
    Marzec M; Liu X; Wong W; Yang Y; Pasha T; Kantekure K; Zhang P; Woetmann A; Cheng M; Odum N; Wasik MA
    Oncogene; 2011 Mar; 30(11):1372-8. PubMed ID: 21102525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
    Marzec M; Zhang Q; Goradia A; Raghunath PN; Liu X; Paessler M; Wang HY; Wysocka M; Cheng M; Ruggeri BA; Wasik MA
    Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20852-7. PubMed ID: 19088198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
    Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
    J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.
    Marzec M; Halasa K; Liu X; Wang HY; Cheng M; Baldwin D; Tobias JW; Schuster SJ; Woetmann A; Zhang Q; Turner SD; Ødum N; Wasik MA
    J Immunol; 2013 Dec; 191(12):6200-7. PubMed ID: 24218456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
    Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
    Bischof D; Pulford K; Mason DY; Morris SW
    Mol Cell Biol; 1997 Apr; 17(4):2312-25. PubMed ID: 9121481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
    Marzec M; Kasprzycka M; Ptasznik A; Wlodarski P; Zhang Q; Odum N; Wasik MA
    Lab Invest; 2005 Dec; 85(12):1544-54. PubMed ID: 16170336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
    Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
    Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
    Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
    Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
    Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K
    Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acetylation of STAT3 at K685 attenuates NPM-ALK-induced tumorigenesis.
    Korai A; Lin X; Tago K; Funakoshi-Tago M
    Cell Signal; 2024 Feb; 114():110985. PubMed ID: 38000524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.
    Zhu H; Vishwamitra D; Curry CV; Manshouri R; Diao L; Khan A; Amin HM
    J Pathol; 2013 May; 230(1):82-94. PubMed ID: 23338972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein.
    Vishwamitra D; Curry CV; Shi P; Alkan S; Amin HM
    Neoplasia; 2015 Sep; 17(9):742-754. PubMed ID: 26476082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
    Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
    Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.
    Zhang Q; Wang HY; Nayak A; Nunez-Cruz S; Slupianek A; Liu X; Basappa J; Fan JS; Chekol S; Nejati R; Bogusz AM; Turner SD; Swaminathan K; Wasik MA
    Am J Pathol; 2022 Aug; 192(8):1186-1198. PubMed ID: 35640677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
    Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC
    Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.